are approved for venous thromboembolism (VTE) prophylaxis. Which agent is superior remains controversial. OBJECTIVE: To compare the effectiveness, complications, and costs of UFH and LMWH as VTE ...
[15] The ENOXACAN 2 trial showed that continuing prophylaxis with enoxaparin until 30 days after surgery significantly reduced the risk of VTE (by 60%, 95% CI 10-82%), from 12% to 4.8%. No ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback